Key facts
- It has raised $8.0M across 1 recorded rounds; the latest was Seed Round ($4.3M) in Apr 2025.
- Notable investors include Highlight Capital, TIFF Investment Management, Cure Ventures, Rivas Capital, Sigmas Group.
- Crosslink Therapeutics has filed 1 Form D with the SEC, most recently May 2025 ($4.3M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Crosslink Therapeutics
Funding rounds
1 roundsAbout Crosslink Therapeutics
Operator of a biologics platform intended to enable targeted cancer treatment using tumor-specific biochemical markers. The company offers a modular biologic domain that assembles therapeutics in the presence of elevated extracellular ATP and can be applied across antibody drug conjugates and radioligand therapies, enabling oncology researchers and pharmaceutical developers to achieve improved tumor targeting and therapeutic effectiveness.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 4
- Website
- xlinktx.com/
- Ownership
- Privately Held (backing)
Crosslink Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Crosslink Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Crosslink Therapeutics in its N-PORT filings yet. We sweep new filings monthly.